Guardant Health (NASDAQ:GH) reported Q2 EPS of ($1.00), $0.21 better than the analyst estimate of ($1.21). Revenue for the quarter came in at $109.1 million versus the consensus estimate of $105.08 million.
GUIDANCE:
Guardant Health sees FY2022 revenue of $460-470 million, versus the consensus of $465.3 million.